Icahn School of Medicine at Mount Sinai

Abbott Laboratories Corporation

Francis Eng

Andrea Branch

David J Hawksworth

Robert N Ziemann

Bryan C Tieman

A Scott Muerhoff

Christopher C Marohnic

April Ahlberg

Kathy Otis

The present disclosure provides detection methods employing HCV core lipid binding domain and DNA binding domain monoclonal antibodies or antibody fragments. In certain embodiments, the lipid binding domain monoclonal antibody or antibody fragment recognizes an epitope in amino acids 141 to 161 of HCV core protein and the DNA binding domain antibody or antibody fragment recognizes an epitope in amino acids 95-123 (e.g., in amino acids 99-117) of HCV core protein.

Detection methods employing HCV core lipid and DNA binding domain monoclonal antibodies

The present disclosure relates to hepatitis C virus (HCV) core and minicore-binding molecules and nucleic acid sequences encoding such molecules. In particular embodiments, the present invention provides HCV core and minicore-binding molecules (e.g., monoclonal antibodies or antibody fragments) with particular light chain and/or heavy chain CDRs (e.g., selected from SEQ ID NOS: 2-4 and 6-8) and methods for using such molecules to detect the presence of HCV core proteins (e.g., mature p21 core protein or minicore proteins) in a sample.

HCV core and minicore binding molecules

Growing community of inventors

New York, NY, United States of America

Francis Eng